Company intelligence / Profile preview

Bio Originals

Las Vegas, Nevada, United States

Ownership: Private
Development stage: Other

Overview

BioOriginals is a biotechnology company dedicated to the development of next-generation regenerative medicines utilizing exosome-based technologies. The company focuses on isolating and engineering high-potency exosomes derived from various cellular sources to treat neurodegenerative diseases, age-related conditions, and chronic inflammatory disorders. By leveraging the natural signaling capabilities of exosomes, BioOriginals aims to deliver targeted therapeutic payloads that promote tissue repair and modulate immune responses. Their research emphasizes the standardization of exosome production to ensure clinical-grade quality and scalability for future therapeutic applications.

Therapeutic areas: ImmunologyNeurologyOther
Modalities: Exosome-based therapyCell therapy
Industry: Biotech

Beyond the preview

Go deeper on Bio Originals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bio Originals.

Explore the full profile